Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.27)
# 1,061
Out of 4,996 analysts
106
Total ratings
48.39%
Success rate
3.6%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTMX CytomX Therapeutics | Initiates: Overweight | $6 | $2.90 | +106.90% | 1 | Sep 22, 2025 | |
| GOSS Gossamer Bio | Reiterates: Overweight | n/a | $2.70 | - | 1 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $405 → $525 | $432.66 | +21.34% | 2 | Sep 10, 2025 | |
| VRNA Verona Pharma | Maintains: Overweight | $90 → $100 | $106.69 | -6.27% | 1 | Jun 11, 2025 | |
| VNDA Vanda Pharmaceuticals | Assumes: Overweight | $13 | $5.10 | +154.90% | 1 | May 14, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $53.85 | +67.13% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $385.74 | +24.44% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $44.12 | +24.66% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $112.10 | -28.64% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $4.46 | - | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $1,015 | $563.90 | +80.00% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 | $272.98 | +48.36% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $446.40 | -50.72% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $13.14 | -23.90% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $5.53 | +17.54% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $61.67 | +16.75% | 1 | Apr 13, 2023 |
CytomX Therapeutics
Sep 22, 2025
Initiates: Overweight
Price Target: $6
Current: $2.90
Upside: +106.90%
Gossamer Bio
Sep 11, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.70
Upside: -
United Therapeutics
Sep 10, 2025
Maintains: Overweight
Price Target: $405 → $525
Current: $432.66
Upside: +21.34%
Verona Pharma
Jun 11, 2025
Maintains: Overweight
Price Target: $90 → $100
Current: $106.69
Upside: -6.27%
Vanda Pharmaceuticals
May 14, 2025
Assumes: Overweight
Price Target: $13
Current: $5.10
Upside: +154.90%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $53.85
Upside: +67.13%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $385.74
Upside: +24.44%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $44.12
Upside: +24.66%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $112.10
Upside: -28.64%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $4.46
Upside: -
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $563.90
Upside: +80.00%
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $272.98
Upside: +48.36%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $446.40
Upside: -50.72%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $13.14
Upside: -23.90%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $5.53
Upside: +17.54%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $61.67
Upside: +16.75%